🔗 Share this article

Given that America continues making unprecedented changes to its vaccine guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccinations throughout the global health crisis and has focused upon alleged deaths following Covid vaccination in her recent time at the FDA.

Proposed Shifts to Pediatric Immunization Program

Agency leaders planned to announce major changes to the childhood immunization program recently, bringing the US with the Danish national calendar, it is understood – a significant shift that would put the US out of step with many the international standard with little proof for public health gain. The planned update has been postponed until the coming year.

Rather than the director of the vaccine center, Høeg is set to speak at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this year.

Consolidating Power at the FDA

The acting appointment could signify a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a renewed priority upon rolling back already-approved immunizations at the FDA.

Høeg has often pushed for halting certain pediatric shot schedules in the US so as to align more in line with the Danish model, a society with universal health coverage and a citizenry about the population of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Doubts Over Qualifications

The appointee has no obvious track record in pharmaceutical research, oversight or management, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, said Jonathan Howard. “She’s never run a scientific study. She is not versed in managing a sizeable institution. She lacks background in drug approvals.”

Previous directors of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that former directors who led the center have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner emphasized.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and each of these need to be managed,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative aspect to the position, which oversees over 5,000 employees. “It is a enormous administrative position, if you perform it correctly,” the former official added.

Response and Contentious Programs

In response to concerns about Dr. Høeg's fitness for the role and whether this selection indicates increased cooperation among agency officials on immunizations, a press secretary stated that the “inquiries stem from flawed premises”.

“This background matches the duties of her job,” the spokesperson explained, citing the period Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious rapid drug-approval program that reportedly concerned her predecessors. “By what process are these medications being picked for this fast-track system? Who makes the choices?” Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

Overall, he remarked, “the FDA seems to be moving towards laxer regulations of most medications, with the exception of immunizations.”

Established History on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if concerning, track record, critics said. She released a research paper using non-validated crowd-sourced reports to determine the incidence of heart inflammation following Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the new federal leadership featured changing regulations for novel immunizations and halting “unnecessary” vaccines, she remarked following the vote on a online show. At the agency, Dr. Høeg has according to sources floated the idea of excluding adolescent males from receiving COVID-19 vaccines.

“She’s an thorough true believer who commences with her conclusions and works backwards to retrofit the science in a highly misleading, untruthful way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|